OA Dr. Christoph Suppan, Universitätsklinik für Innere Medizin, Graz, diskutiert die im Presidential Symposium vorgestellten Brustkrebsstudien und erklärt deren Einfluss auf die klinische Praxis.

Quelle: ESMO 2018

Abstracts

LBA1_PR – IMpassion130: Results from a global, randomised, double-blind, phase 3 study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC)

Schmid P et al.

LBA3_PR – Alpelisib (ALP) + Fulvestrant (FUL) for advanced breast cancer (ABC): results of the Phase 3 SOLAR-1 trial

Fabrice André (Villejuif, FR)

LBA2_PR – Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3

Cristofanilli M et al.